<?xml version='1.0' encoding='utf-8'?>
<document id="22391553"><sentence text="Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects." /><sentence text="Eltrombopag is an orally bioavailable thrombopoietin receptor agonist that is approved for the treatment of chronic idiopathic thrombocytopenic purpura" /><sentence text=" It is being developed for other medical disorders that are associated with thrombocytopenia" /><sentence text=" Patients with human immunodeficiency virus (HIV) may suffer from thrombocytopenia as a result of their HIV disease or coinfection with hepatitis C virus (HCV)" /><sentence text=" HIV medications, particularly ritonavir (RTV)-boosted HIV protease inhibitors, are involved in many drug interactions"><entity charOffset="31-40" id="DDI-PubMed.22391553.s5.e0" text="ritonavir" /></sentence><sentence text=" This study evaluated the potential drug-drug interaction between eltrombopag and lopinavir (LPV)/RTV"><entity charOffset="82-91" id="DDI-PubMed.22391553.s6.e0" text="lopinavir" /><entity charOffset="93-96" id="DDI-PubMed.22391553.s6.e1" text="LPV" /><pair ddi="false" e1="DDI-PubMed.22391553.s6.e0" e2="DDI-PubMed.22391553.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22391553.s6.e0" e2="DDI-PubMed.22391553.s6.e1" /></sentence><sentence text=" Forty healthy adult subjects enrolled in this open-label, three-period, single-sequence crossover study received a single 100-mg dose of eltrombopag (period 1), LPV/RTV at 400/100 mg twice daily (BID) for 14 days (period 2), and LPV/RTV at 400/100 mg BID (2 doses) with a single 100-mg dose of eltrombopag administered with the morning LPV/RTV dose (period 3)"><entity charOffset="162-164" id="DDI-PubMed.22391553.s7.e0" text="LPV" /><entity charOffset="230-232" id="DDI-PubMed.22391553.s7.e1" text="LPV" /><entity charOffset="337-339" id="DDI-PubMed.22391553.s7.e2" text="LPV" /><pair ddi="false" e1="DDI-PubMed.22391553.s7.e0" e2="DDI-PubMed.22391553.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22391553.s7.e0" e2="DDI-PubMed.22391553.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22391553.s7.e0" e2="DDI-PubMed.22391553.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22391553.s7.e1" e2="DDI-PubMed.22391553.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22391553.s7.e1" e2="DDI-PubMed.22391553.s7.e2" /></sentence><sentence text=" There was a 3-day washout between periods 1 and 2 and no washout between periods 2 and 3" /><sentence text=" Serial pharmacokinetic samples were collected during 72 h in periods 1 and 3 and during 12 h in period 2" /><sentence text=" The coadministration of 400/100 mg LPV/RTV BID with a single dose of 100 mg eltrombopag decreased the plasma eltrombopag area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC(0-âˆž)) by 17%, on average, with no change in plasma LPV/RTV exposure"><entity charOffset="36-38" id="DDI-PubMed.22391553.s10.e0" text="LPV" /><entity charOffset="265-267" id="DDI-PubMed.22391553.s10.e1" text="LPV" /><pair ddi="false" e1="DDI-PubMed.22391553.s10.e0" e2="DDI-PubMed.22391553.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22391553.s10.e0" e2="DDI-PubMed.22391553.s10.e1" /></sentence><sentence text=" Adverse events (AEs) reported in period 2 were consistent with known LPV/RTV AEs, such as diarrhea, abdominal pain, nausea, vomiting, rash, and fatigue"><entity charOffset="70-72" id="DDI-PubMed.22391553.s11.e0" text="LPV" /></sentence><sentence text=" No subjects withdrew due to AEs, and no serious AEs were reported" /><sentence text=" These study results suggest that platelet counts should be monitored and the eltrombopag dose adjusted accordingly if LPV/RTV therapy is initiated or discontinued"><entity charOffset="119-121" id="DDI-PubMed.22391553.s13.e0" text="LPV" /></sentence><sentence text="" /></document>